Stock & analyst
information

This page contains a range of information related to Astellas’ stock performance, share status, shareholder return, dividend details, analyst coverage, issuer ratings, and more.

Stock chart

Performance

Current share status

As of March 31, 2025

Number of shareholders: 408,888

Common stock authorized: 9,000,000,000

Common stock issued: 1,809,663,075 

Current share status

Top ten (10) principal shareholders in the register of shareholders: 

  Name of shareholdersNumber of shares held (Thousand) Percentage of shares held (%) 
1The Master Trust Bank of Japan, Ltd.(trust account)359,70919.88
2Custody Bank of Japan, Ltd. (trustaccount)145,230 8.02
3Goldman, Sachs & Co. Reg60,7293.35
4State Street Bank and Trust Company50500154,1882.99 
5Nippon Life Insurance Company51,5882.85 
6State Street Bank West Client - Treaty50523441,4722.29
7SMBC Nikko Securities Inc.28,5381.57
8JPMorgan Securities Japan Co., Ltd.27,5031.52
9JPMorgan Chase Bank 38578126,3821.45
10State Street Bank and Trust Company50510320,9141.15

Number of shares held are presented by discarding the numbers down to the thousand, and percentage of shares are presented by discarding the numbers down to the third decimal.

Basic information about shares

Fiscal year endMarch 31
Annual shareholders' meeting 
June
Record date for dividendYear-end dividend - March 31
Interim dividend - September 30
Note: In accordance with the Company's Articles of Incorporation, if cash dividends are not claimed for three (3) full years from the day of commencement of payment, the Company shall be relieved of the obligation to make such payment. 
Stock trading unit100 shares
Stock exchange listingsTokyo Stock Exchange
Ticker code4503
Administrator of Shareholder Registry

Address: 1-4-1 Marunouchi, Chiyoda-ku, Tokyo 100-8233
Sumitomo Mitsui Trust Bank, Limited
https://www.smtb.jp/personal/agency/index.html (Japanese page only)


Administrative Office (Inquiries)
Address: 1-8-4 Izumi 2-chome, Suginami-ku, Tokyo 168-0063
Sumitomo Mitsui Trust Bank, Limited, Stock Transfer Agency Department
Tel: 0120-782-031 (toll-free, calls from within Japan only)

Agency Contact
Sumitomo Mitsui Trust Bank, Limited, Nationwide Branches
https://www.smtb.jp/personal/branch/index.html (Japanese page only)

The Account Manager of the Special AccountPlease note that the inquiries and intermediary contact are the same as those for the Administrator of Shareholder Registry listed above.
Articles of incorporationArticles of Incorporation (pdf 190KB)
Share handling regulationsShare Handling Regulations (pdf161KB)
Special benefits program for shareholdersNone

Shareholder Return

Basic policy on shareholder return:

The Company works aggressively towards increasing enterprise value on a continual basis and, as a consequence, improves its return to shareholders. While putting priority on business investment to assure future growth, the Company strives to increase dividend payments stably and continuously based on its medium- to long-term profit growth on a consolidated basis. Further, the Company flexibly acquires its own shares whenever necessary to increase capital efficiency and shareholder return. 

1

Top priority is investment for business growth

2

Raise dividend level aligned with profit / cashflow plan and actual performance throughout CSP2021 period

3

Flexibly execute share buyback by excess cash

Shareholder Return 

Record date for dividend:

Year-end dividend - March 31 Interim dividend - September 30

Announcement of the 20th term year-end dividend

The company would like to inform you that the following resolutions have beenmade at the Board of Directors meeting held on April 25, 2025 regarding thepayment of year-end dividends for the 20th term (April 1, 2024 to March 31, 2025).

 

1. Year-end dividend: 37 yen per share 
2. Effective date of year-end dividend: Tuesday, June 3, 2025 (Payment start date)

Historical data of dividend and DOE

IFRS
 Dividend (Unit: Yen / share) 
 Interim dividend Year-end dividend Total Annual dividend DOE* (%)
FY2025
39
(Planned)39
(Planned)78
(Planned)  
FY20243737748.5
FY20233535708.1
FY20223030607.3
FY20212525506.5
FY2020
2121425.8
FY20192020405.9

FY20181919385.8
FY20171818365.7

*DOE: Dividend On Equity ratio. DOE= (The total annual dividend payout) / (Shareholders' Equity) x 100 (%)

 

Notes: The Astellas Group has adopted the International Financial Reporting Standards ("IFRS"), effective from the fiscal year ended March 31, 2014.

 

Notes: In accordance with the Company's Articles of Incorporation, if cash dividends are not claimed for three (3) full years from the day of commencement of payment, the Company shall be relieved of the obligation to make such payment. 

Share buyback

Acquisition periodShares acquiredTotal acquisition cost
(thousand yen)		PDF
Feb.7 - Mar. 15 202326,188,50049,999,962pdf(113KB)
Feb. 3 - Mar. 9 2022 25,935,500  49,999,849 pdf(114KB)
pdf(107KB)
Nov. 1 2019 - Jan. 31 202027,036,100 49,999,815 pdf(179KB)
pdf(169KB)
pdf(303KB)
Feb. 1 - Mar. 20 2019 35,368,900 59,999,863 pdf(167KB)
Jun. 1 - Sep. 20 2018 55,475,800 99,999,960pdf(301KB)
Feb. 1 - Mar. 23 2018 39,577,500 59,999,993 pdf(167KB)
Jul. 31 - Oct. 31 2017 49,298,000 69,999,960 pdf(121KB)
Feb. 1 - Mar. 22 2017 30,000,000 45,525,514 pdf(189KB)
Oct. 31 - Dec. 22 2016 30,000,000 45,895,995 pdf(189KB)
Feb. 1 - Mar. 1 2016 17,000,000 27,455,199 pdf(41KB)
Nov. 2 - Dec. 1 2015 16,000,000 27,979,393 pdf(41KB)
Aug. 3 - Aug. 26 2015 15,000,000 28,211,012 pdf(40KB)
May. 28 - Jul. 10 2015 20,000,000 35,619,462  pdf(180KB) 
Feb. 3 - Mar. 13 2015 15,000,000 28,214,129 pdf(62KB) 
Nov. 5 - Dec. 12 2013 5,037,500 29,999,950 pdf(41KB) 
Feb. 4 - Mar. 18 2013 6,000,000 29,847,367 pdf(22KB) 
Nov. 5 - Dec. 10 2012 4,800,000 19,524,140 pdf(23KB) 
Nov. 9 - Dec. 11 2009 8,200,000 26,961,398 pdf(24KB) 
Nov. 7 - Dec. 12 2008 9,000,000 35,068,665 pdf(24KB) 
Aug. 4 - Aug. 21 2008 10,000,000 48,351,108 pdf(24KB) 
May. 15 - Jun. 20 2008 9,085,500 39,999,735 pdf(24KB) 
Dec. 3 2007 - Jan. 18 2008 8,000,000 38,684,248 pdf(24KB) 
Aug. 29 - Sep. 10 2007 8,300,000 43,088,442 pdf(23KB) 
Oct. 5 - Dec. 19 2006 29,046,300 149,999,577 pdf(23KB) 
Aug. 2 - Sep. 20 2006 14,985,400 69,911,303 pdf(23KB) 
Nov. 8 - Dec. 8 2005 5,979,300 26,999,916 pdf(8KB) 
Aug. 3 - Aug. 31 2005 5,000,000 19,172,363 pdf(8KB) 

Cancellation of Treasury stock 

Date of cancellationShares cancelledShares cancelled as a percentage of all outstanding shares issued prior to the cancellationPDF
Mar 29, 2023 26,188,500 1.44% pdf(113KB)
Mar 29, 2022 25,935,500 1.40% pdf(115KB)
Feb 14, 2020 27,036,100 1.45% pdf(179KB)
May 31, 201991,000,0004.60%(pdf 279KB)
May 31, 2018 89,000,000 4.30%pdf(281KB)
May 31, 2017 85,000,000 3.95% pdf(263KB)
June 20, 201668,000,000 3.06% pdf(74KB)
May 29, 201538,000,000 1.68% pdf(23KB)
May 30, 2014 25,000,000 1.09% pdf(25KB)
May 31, 2013 11,000,000 2.40% pdf(24KB)
May 31, 2010 8,000,000 1.68% pdf(34KB)
June 23, 2009 28,000,000 5.56%  pdf(30KB)
June 24, 2008 15,000,000 2.89% pdf(32KB)
June 26, 2007 45,000,000 7.98% pdf(23KB)
May 31, 2006 10,000,000 1.74% pdf(23KB)

as of July 7, 2025

List of analysts of securities companies and research companies who makerecommendations and reports of Astellas' performance, etc

Company namePerson in charge
BofA Securities Japan Co., Ltd. Koichi Mamegano 
Citigroup Global Markets Japan Inc. Hidemaru Yamaguchi 
Daiwa Securities Co. Ltd. Kazuaki Hashiguchi 
Goldman Sachs Japan Co., Ltd. Akinori Ueda 
Jefferies Japan Limited Stephen Barker 
JPMorgan Securities Japan Co., Ltd. Seiji Wakao 
Macquarie Capital Securities (Japan) Limited Tony Ren 
Mizuho Securities Co., Ltd. Yuriko Ishida
Morgan Stanley MUFG Securities Co., Ltd. Shinichiro Muraoka 
Nomura Securities Co., Ltd. Hiroyuki Matsubara 
Sanford C. Bernstein Japan KK Miki Sogi 
SMBC Nikko Securities Inc. Hiroshi Wada 
UBS Securities Japan Co., Ltd. Fumiyoshi Sakai 

Note: This list is based on the currently available information regarding coverage forAstellas by the securities analysts/researchers. The list may not be complete and issubject to change.

 

Please note that any opinions, estimates or forecasts regarding Astellas'performance, businesses, products, and technologies made by the analysts at listedabove or the analysts not listed above, are theirs alone and not those of Astellas orits management.

 

Astellas provides this information solely for the purpose of introducing theanalysts/researchers to the investors. Astellas does not imply its endorsement of orconcurrence with any information, estimates, opinions, recommendations andinformation by these analysts/researchers.

 

If you actually intend to trade stock, please make such stock traded in accordancewith your own judgment.

(As of March 23, 2021) 

Institution Rating
Moody'sA3
Rating and Investment Information, Inc. (R&I)AA

Astellas' status in Action to Implement Management that is Conscious of Cost of Capital and Stock Price is as follows.

Analysis of current situation

  • Recognized that awareness of cost of capital and stock price is essential for sustainable growth and increased corporate value
  • Aiming to ensure return on capital in excess of cost of capital, WACC is calculated and verified on a regular basis and used in business investment decision-making after a clear assessment of the cost of capital
  • On the other hand, it is recognized that stock prices in the pharmaceutical sector are heavily influenced by business performance and the future pipeline value
  • Implement management based on the evaluation of future pipeline value as an indicator to realize medium- and long-term corporate value enhancement, rather than capital profitability indicators such as ROE and ROIC, which are calculated as actual values for a single fiscal year

Planning

  • A medium-term plan “Corporate Strategic Plan 2021” was announced in May 2021. The Performance Goals set are ‘Revenue', ‘Pipeline Value' and ‘Core Operating Profit Margin’
  • Aspire to be recognized as a company with a market capitalization exceeding 7 trillion yen by achieving the Performance Goals above 
  • Revised and disclosed capital allocation policy in line with Corporate Strategic Plan 2021 (see figure below for details) 
  • When opportunities for capital investment to realize future growth are identified, raise funds as necessary, while carefully assessing and managing the appropriate level of capital reserves 
  • Maintain a balanced capital structure necessary to ensure future cash flows and a stable operational foundation when implementing large-scale acquisitions 

Initiatives

  • Adopt Performance-linked Stock Compensation Scheme (measurement index: TSR*) as medium- to long-term incentive remuneration for Directors and Top Management, and establish a system that contributes to the enhancement of corporate value and shareholder value 
  • Review the corporate value (theoretical value) calculated from the "pipeline value" and other factors on a regular basis, monitor progress, and implement business decisions necessary for enhancing corporate value 
  • When making business investments, evaluate them by calculating NPV using the DCF method with WACC, and make decisions aimed at achieving a return that exceeds the cost of capital 
  • To achieve appropriate market valuation and share price, including future growth potential, and to reduce the cost of capital, promote proactive investor relations activities to engage with investors and enhance comprehensive information disclosure
  • In accordance with the capital allocation policy, raise the dividend level aligned with profit / cashflow plan and actual performance, and flexibly execute share buybacks
  • In accordance with the increase in interest-bearing debt associated with the acquisition of Iveric Bio, carry out appropriate debt management with a focus on cash flow and aim to promptly restore financial soundness 

: Total Shareholder Return. Total investment yield for shareholders, including capital gains and dividends 

Cautionary statement

The information disclosed in this part of the Astellas Website is provided for better understanding of Astellas by stakeholders including shareholders and investors, but is intended to neither solicit nor recommend the purchase of the Astellas' stock.

  • changes in general economic conditions in, and the laws and regulations relating to, Astellas' markets, 
  • currency exchange rate fluctuations, 
  • delays in new product launches, 
  • the inability of Astellas to market existing and new products effectively, 
  • Astellas' ability to continue research and develop products accepted by customers in highly competitive markets and 
  • infringements of Astellas' intellectual property rights.

(2) The pages include the information regarding pharmaceuticals including the ones under development, however, they are not intended for advertisement or medical advice at all.

 

(3) Addition, change or deletion of the information may occur at anytime without notice. 

Keep exploring

Astellas employees work on a laptop and examine the company’s strong financial results.

Financial Results Library

Two Astellas employees shake hands, symbolizing the company’s goal to maximize its return to shareholders.

Contact Us

(For Institutional Investors and Securities Analysts)